clairop

Can Crohn's Disease Stay Mild Long Term?

Yes, for some people. Cohort data on how often Crohn's stays mild, the factors linked to a worse course, and why monitoring matters even when you feel well.

Clairop Team20 min read

Photo: Arlind Photography / Unsplash

The short answer

For some people, yes. Long remissions and years of quiet disease are well documented, but studies following people for 5 to 20 years show many develop strictures, fistulas or surgery. Risk is not the same for everyone, and symptoms alone can understate inflammation, so regular monitoring is what tells you which path you are on.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Yes, Crohn's disease, a chronic inflammatory bowel disease that can affect any part of the digestive tract, can stay mild for years in some people, and long remissions are well documented. But it can change its behavior over time, and cohort studies following people for 5 to 20 years show that a sizable share develop strictures, fistulas or need surgery. Which path you are on is not obvious from how you feel, which is why monitoring matters even when things are quiet.

If you were recently diagnosed with a mild picture and are asking this question, you are in good company. A thread in r/CrohnsDisease titled can Crohn's stay mild long-term drew well over a hundred replies. A common theme is people describing one or two decades with few flares and no surgery. Another common theme is the worry that sits underneath it, which is the story of years of quiet disease followed by a sharp turn. Both stories are real, and the research explains why.

This guide covers what "mild" actually means, what the long-term cohort data show, the factors linked to a worse course, why symptoms alone can be a poor guide, how monitoring works, and how a simple symptom log helps you notice drift early. It does not tell you whether to start, stop or change any treatment. That decision belongs to you and your gastroenterologist, and our guide on whether to start biologics for mild Crohn's covers the evidence behind it.

Can Crohn's disease stay mild long term?

For some people, yes. Population studies show that a minority have little progression over many years, and about one in ten has prolonged clinical remission in the older cohort data. At the same time, half of all people in the long-term population studies had an intestinal complication within 20 years (Peyrin-Biroulet 2010).

That review pulled together the population-based studies with long follow-up, meaning studies that followed everyone in a region rather than only people who ended up at specialist centers. It reported that about one-third of people had a stricturing or penetrating complication at the time of diagnosis, that steroid dependency occurred in about a third, and that the annual risk of a hospital admission was around 20%. It also noted that the effect of newer treatment paradigms on the natural history was poorly known. Most of these cohorts were assembled before today's treatment options were widely used, so they describe what happens on average, not what happens to you.

A Norwegian cohort followed 237 people with Crohn's from diagnosis for ten years. The cumulative probability of surgery was 37.9%, and 53% had developed stricturing or penetrating disease by year ten. But 44% were in clinical remission during the last five years of follow-up, and the authors concluded that the prognosis seemed better than previously reported (Solberg 2007).

Read those two findings together. Crohn's is a condition that, on average, tends to produce complications over a couple of decades. It is also a condition where long quiet stretches are common. Both are true, and people in the community describe both. A long-standing review of the natural history of the disease says that although prolonged remission may occur, discrete periods of symptomatic disease can reappear over many decades (Freeman 2014).

What does "mild Crohn's" actually mean?

Mild can describe how much inflammation is present now, or it can describe how likely your disease is to progress. A gastroenterologist writing in 2024 defined mild Crohn's in terms of low likelihood of progression, usually older age at diagnosis with limited anatomic extent, such as limited ileitis or scattered shallow erosions in the colon (Ha 2024).

That distinction is easy to miss, and it is the heart of the confusion in online threads. In a second r/CrohnsDisease thread asking whether mild Crohn's is a thing, the top replies make the same point in plain language: mild can mean a mild level of active inflammation right now, or it can mean a disease course that is not aggressive. The first can change from one month to the next. The second is a statement about the future, which is harder to know.

Two ideas help here:

  • Mild activity is a snapshot. It means you have few symptoms and, typically, normal blood counts, albumin, CRP and fecal calprotectin, with no fever, weight loss or obstructive symptoms. It describes today.
  • Mild disease course is a trajectory. It means the disease has not been causing damage and is unlikely to. It can only be judged over time, with repeated assessment.

One more point. A 2023 review estimated that 20 to 30% of people with Crohn's have a mild disease course (Claytor 2023). A 2024 interview with a gastroenterologist said studies show 40 to 50% of people diagnosed with mild Crohn's remain mild up to 15 years after diagnosis, especially when it was found incidentally (Ha 2024). Those numbers differ because the groups and definitions differ, and neither is a forecast for an individual. If someone quotes you a single percentage, ask what group it was measured in.

How often does mild Crohn's progress?

In a European cohort of 488 people followed for five years from diagnosis, 14% of those with non-stricturing, non-penetrating disease at diagnosis progressed to stricturing or penetrating disease. Over the same period 22% had surgery and 36% were hospitalized because of Crohn's (Burisch 2019).

That study followed people from 29 centers covering a large background population, rather than a single referral hospital, so it is closer to what happens in everyday practice. Note what the 14% means. It is about the people who start without complications, which is the group most likely to be described as mild. For most of them, five years later, the behavior of the disease had not changed.

The American community study from Olmsted County, Minnesota, used medical records from 306 residents diagnosed between 1970 and 2004. At diagnosis, 81.4% had non-stricturing, non-penetrating disease. The cumulative risk of developing either complication was 33.7% at 5 years and 50.8% at 20 years. Among 249 people who started without complications, 66 changed behavior after the first 90 days (Thia 2010).

Put side by side:

CohortFollow-upWhat was reported
Norway, 237 people (Solberg 2007)10 years53% stricturing or penetrating by year 10; surgery 37.9%; 44% in clinical remission in the last 5 years
Olmsted County, 306 people (Thia 2010)up to 20 yearsComplications 33.7% at 5 years, 50.8% at 20 years
Europe, 488 people (Burisch 2019)5 years14% of non-complicated disease progressed; surgery 22%; hospitalized 36%
Pooled population studies (Peyrin-Biroulet 2010)up to 20 yearsAbout 10% with prolonged remission; half with an intestinal complication within 20 years

Two cautions. These cohorts mix everyone with Crohn's, mild and not mild, so they overstate progression for the truly low-risk group and understate it for the high-risk group. And most predate the current era of early, targeted treatment, so they describe the disease as it behaved in those decades, not as it must behave for you now. What they do show reliably is the shape of the risk: it is not zero, it accumulates over time, and it is not evenly spread.

What factors predict a worse course?

The best-replicated markers at diagnosis are age under 40, perianal disease and needing steroids for the first flare. In a French referral cohort of 1,123 people, these carried odds ratios of 2.1, 1.8 and 3.1 for a disabling course over the next five years (Beaugerie 2006).

That study has important limits. The "disabling" definition was broad, and the rate of disabling disease was 85.2% in a tertiary referral center, which tells you how definition-dependent that word is. A separate retrospective cohort of 361 people found a 57.9% rate with its own criteria, confirmed perianal lesions, steroids for the first flare and ileocolonic location as markers, did not confirm age under 40, and concluded that the predictive performance of the models was low (Loly 2008).

Other studies point the same direction on different measures:

  • Location. Ileal, ileocolonic and upper gastrointestinal location were linked to a change in behavior relative to colonic disease in the Olmsted cohort, and perianal disease was barely significant (Thia 2010). In the Norwegian cohort, terminal ileal location, stricturing, penetrating behavior and age under 40 were independent risk factors for later surgery (Solberg 2007).
  • Early flare frequency. In a cohort of 163 people who began with non-stricturing, non-penetrating disease, ileal location was associated with a later stricturing pattern and a high number of flares per year with a penetrating pattern (Louis 2003).
  • Weight loss and stricturing at diagnosis. In the 361-person cohort above, stricturing behavior and weight loss over 5 kg at diagnosis were independently associated with the time to severe disease (Loly 2008).
  • Smoking. A meta-analysis of 33 studies found smokers had increased odds of flare (OR 1.56), of a first surgery (OR 1.68) and of a second surgery (OR 2.17) compared with nonsmokers, and outcomes in ex-smokers were comparable to nonsmokers (To 2016). In an intervention study, people who stopped smoking for more than a year had a flare risk that did not differ from nonsmokers (Cosnes 2001). Our guide on whether smoking makes Crohn's worse goes deeper.

The British Society of Gastroenterology lists four high-risk features: complex stricturing or penetrating disease at presentation, perianal fistulizing disease, age under 40 at diagnosis and needing steroids to control the index flare. It adds that their predictive power is limited (Lamb 2019). That sentence is the honest summary of this whole section. These factors shift the odds. They do not read your future.

The same gastroenterologist who defined mild Crohn's in 2024 pointed to the other end of the spectrum, noting that the factors linked to a low likelihood of progression are few, mainly older age at diagnosis combined with limited extent of disease (Ha 2024). Neither list is a verdict. Both are reasons to monitor.

Can you have Crohn's inflammation with no symptoms?

Yes. Symptoms and inflammation correlate only loosely. In an analysis of the SONIC trial, 53% of people in clinical remission by CDAI score had mucosal healing, which means roughly half did not. Other people with normal markers still had symptoms. The authors concluded that clinical symptoms scored by the CDAI are not a reliable measure of the underlying inflammation (Peyrin-Biroulet 2014).

That is a trial in people with moderate to severe disease who were on treatment, so the numbers cannot simply be transplanted onto mild disease. The principle holds more widely, though. A Scottish study of 918 people with Crohn's found that a raised fecal calprotectin at a routine visit was associated with later progression, defined as a composite of change in disease behavior, hospitalization and resection, independent of symptoms or disease location. A cutoff of 115 micrograms per gram carried a hazard ratio of 2.4 (Kennedy 2019). The authors concluded that it is important to screen even asymptomatic patients for mucosal inflammation. It was a retrospective study from one center, so it shows an association, not that acting on a number changes the outcome.

This is the reason the phrase "I feel fine" is a good sign but not a closed case. If you want a deeper look at one test, our guides on high calprotectin with no symptoms and on whether calprotectin can be normal with Crohn's walk through the opposite mismatches.

Why does monitoring matter if you feel fine?

Because the disease can be silent until it is not. The 2024 interview put it as clinically silent or indolent until it is not, and said not all people with mild Crohn's need maintenance treatment but all should have long-term monitoring (Ha 2024). Guidelines build monitoring around that logic.

The international STRIDE-II consensus, based on a systematic review of 435 manuscripts and votes by 89 experts, set clinical remission and endoscopic healing as long-term targets in Crohn's. It set symptom relief and normalization of blood and stool markers such as CRP and calprotectin as short-term targets, and said transmural healing should be assessed as a measure of depth of remission (Turner 2021). In plain terms, symptoms are one of several things measured, not the only one.

The American Gastroenterological Association made 11 conditional recommendations on biomarkers. For people in symptomatic remission it suggests a biomarker and symptom-based monitoring strategy over symptoms alone. A fecal calprotectin under 150 micrograms per gram plus a normal CRP rules out active inflammation, and elevated markers in this setting merit confirmation with endoscopy before any change in treatment. In people with mild symptoms, neither normal nor elevated biomarkers alone are accurate enough to say whether the disease is endoscopically active (Ananthakrishnan 2023).

A Lancet seminar on Crohn's says assessing disease extent and prognostic factors is central to decisions, and that current strategies aim for deep and long-lasting remission with tight, frequent control of inflammation, adjusted on the basis of that assessment (Torres 2017). Whether any of that applies to you, and when, is a conversation for your care team.

There is also outcome data suggesting why the goal is deeper than feeling well. In people with early, moderate to severe Crohn's from the CALM trial, those in deep remission had a lower risk of major adverse outcomes in follow-up (adjusted hazard ratio 0.19) (Ungaro 2020). That trial was in a different group from mild disease, and it does not tell mild-disease patients what to do. It does explain why monitoring and treatment targets are framed around inflammation as well as symptoms.

What does monitoring usually involve?

For someone with mild disease, it typically means periodic symptom review, blood tests such as CRP, hemoglobin and iron, fecal calprotectin, weight, and imaging or ileocolonoscopy at intervals your gastroenterologist chooses. A 2024 expert interview described annual or twice-yearly assessments for people with low-risk, mild disease (Ha 2024).

Those intervals are one expert's practice, not a rule, and your own schedule depends on your disease and what your team sees. What the pieces do:

ToolWhat it tells youMain limit
SymptomsHow you feel and function day to dayCan understate or overstate inflammation
WeightA simple sign of nutrition and ongoing inflammationChanges slowly and has many causes
Hemoglobin, ferritinAnemia and iron stores can hint at ongoing activityMany non-Crohn's causes
CRPSystemic inflammation in bloodLess sensitive in mild or localized disease
Fecal calprotectinInflammation in the bowel lining, best in the colonLess reliable for small bowel disease
Ileocolonoscopy, capsule, MR or ultrasoundDirect look at the bowel wallInvasive, costly or less available

The interview author named four markers followed most often, CRP, fecal calprotectin, hemoglobin and iron, and called weight a critical vital sign for Crohn's. The same author said that if ferritin or iron stores are falling and weight is also changing, further evaluation may be needed (Ha 2024). How often you are scoped is covered in our guide on how often to have a colonoscopy with Crohn's, and intestinal ultrasound versus colonoscopy compares a less invasive option.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

How does a symptom log help you catch drift early?

A dated log turns a vague sense that things are slipping into something your doctor can act on. Symptoms alone are an imperfect guide to inflammation, but they are the part you can record every day, and they are the only part available between tests. A log makes slow change visible that memory smooths over.

The value is in the combination. A symptom log by itself cannot say whether you are inflamed. A set of lab results by itself cannot say how you have been living. Together, they let you and your gastroenterologist see whether a normal number sits next to a good three months or a bad one, and whether a rising number sits next to a change you had stopped noticing.

A short log is enough:

  1. Daily: number of bowel movements, whether any woke you at night, pain from 0 to 10, any visible blood, and a one-word energy rating.
  2. Weekly: weight, taken on the same scale at a similar time.
  3. Beside it: every test with date, lab, units and result. Calprotectin, CRP, hemoglobin, ferritin, and the date and finding of any scope or scan.
  4. At each appointment: what changed since the last visit, in numbers, such as "night-time stools on 6 of the last 14 nights, up from none".

What counts as drift? These are patterns worth raising, not diagnoses: a gradual rise in night-time bowel movements, loose stools becoming the new normal over several weeks, new or changing pain, weight loss, falling energy, or a calprotectin or CRP that creeps up between tests. Our guide on how to tell if you are in a Crohn's flare lists more, and whether a symptom tracker can predict a flare is honest about what a log can and cannot do.

A symptom tracker such as Clairop, which is free to download, keeps this kind of log and can build a summary for appointments; see how it works. Any notes app or paper diary does the same job if you will actually use it. Our guide on how to prepare for a GI doctor appointment covers what to bring.

What can you do besides wait and watch?

You can do several things that sit within your own control and your care team's guidance, none of which involve changing medicine on your own. Know your own risk factors, keep appointments and test dates, and ask the questions that make your plan explicit.

  • Ask where your disease sits and what your risk profile is. Location, behavior at diagnosis, perianal involvement and age at diagnosis are the starting points for the factors above.
  • Ask what "mild" means in your chart. Is it a statement about current inflammation, or about expected course? What is the plan if a marker rises?
  • Ask how often you will be tested, with what. Calprotectin and CRP, scans, scopes, and who orders them. Our list of questions to ask your doctor about Crohn's is a place to start.
  • If you smoke, talk about stopping. This is one of the few modifiable factors with consistent data behind it (To 2016).
  • Do not stop or change treatment on your own. If you are already on medicine and in remission, what the evidence says about stopping Crohn's medication is for information only, and the decision is made with your prescriber.

Fatigue is its own topic in quiet disease, and Crohn's fatigue in remission explains why you can feel worn out even when numbers look good. And when you are thinking about the long view, whether you can have a normal life with Crohn's is the encouraging counterpart to this article.

When should you see a doctor promptly?

Contact your gastroenterologist or seek urgent care for new or worsening symptoms that may signal a complication or a flare. Do not wait for your next scheduled review.

  • Blood in your stool, or black or tarry stools
  • Unexplained weight loss
  • Fever, or severe or worsening abdominal pain
  • Persistent vomiting, a swollen belly, or being unable to pass stool or gas
  • Night-time diarrhea that is new or increasing
  • A new painful lump, swelling or discharge near the anus
  • Signs of anemia, such as unusual breathlessness, dizziness or pallor
  • Severe symptoms of dehydration

If you have severe pain with vomiting or cannot pass stool or gas, seek emergency care. These are general guides, not a substitute for your own medical advice.

How was this article put together?

Every figure here comes from a cohort study, guideline, trial or review that was opened and checked against its abstract or full text in November 2026, and is linked inline. One figure, the 40 to 50% mild-course estimate, comes from a clinician interview rather than a study, and is labeled that way. Reddit threads were used only to see what people ask, never as medical evidence. Clairop is a symptom tracker, not a medical service, and this article is not medical advice.

What is the realistic outlook?

Hopeful and uncertain at once. A review of epidemiology and natural history notes that Crohn's is incurable, begins in young adulthood and lasts a lifetime, with strictures and fistulas more frequent in ileal disease and Crohn's colitis often remaining uncomplicated for many years (Cosnes 2011). That is the sober part.

The hopeful part is that long quiet stretches are normal, that the Norwegian authors judged prognosis better than previously reported, and that tools for spotting inflammation, such as calprotectin and intestinal ultrasound, are now part of routine care in many places. In r/CrohnsDisease, many people describe long remissions. A smaller number describe a turn after many calm years. The research supports both stories and says that regular objective check-ins are how you find out which one you are in sooner rather than later.

The honest short version for a recent diagnosis is this. You do not need to assume the worst, and you should not assume nothing will change. Learn your own risk factors, keep a clear record, show up for testing, and keep treatment decisions in the hands of the people who can see your results.

Common myths about mild Crohn's

  • "Mild means it will stay mild." Not necessarily. Disease behavior changed in a meaningful share of people in every cohort above, including in those who started without complications.
  • "If I feel fine, the inflammation is gone." Symptoms and inflammation can diverge in both directions, which is why guidelines pair symptoms with biomarkers.
  • "A normal test means I am done being checked." One normal result is a data point. Calprotectin in particular is less sensitive for small bowel disease.
  • "Everyone with Crohn's ends up with surgery." Not so. Surgery rates in the cohorts above ranged from 22% over five years to 37.9% over ten, which is substantial but far from everyone, and the data predate much of today's treatment.
  • "Risk factors tell me my future." They shift probabilities. Guidelines note their predictive power is limited.
  • "Monitoring means I am being treated for something." Monitoring is how you find out whether anything needs to change. Whether it does is a separate decision.

Frequently asked questions

Can Crohn's disease stay mild for the rest of your life?
For some people it can. In a Norwegian population cohort, 44% were in clinical remission for the last five of ten years of follow-up. But in the same cohort 90% relapsed at least once and 53% developed stricturing or penetrating disease by year ten. Nobody can promise it will stay mild, which is why monitoring continues even in quiet years.
What percentage of people with Crohn's disease have mild disease?
A 2023 review estimated that 20 to 30% of people with Crohn's have a mild disease course. A gastroenterology interview in 2024 put it differently, saying 40 to 50% of those diagnosed with mild disease stay mild up to 15 years. Both figures are estimates from different groups and definitions of mild, so treat them as ranges, not predictions.
Does mild Crohn's disease get worse over time?
It can. In a European inception cohort, 14% of people with non-stricturing, non-penetrating disease at diagnosis had progressed to stricturing or penetrating disease within five years. In an American community cohort the cumulative risk of such complications was 33.7% at 5 years and 50.8% at 20 years. Many people never progress, and risk factors help sort who is more likely to.
What makes Crohn's disease more likely to progress?
Factors linked to a worse course in cohort studies include diagnosis before age 40, perianal disease, needing steroids for the first flare, ileal or ileocolonic location, stricturing behavior at diagnosis, weight loss, and active smoking. The British Society of Gastroenterology notes that the predictive power of these features is limited, so they inform risk but do not decide it.
Can you have Crohn's disease with no symptoms?
Yes. Symptoms and inflammation do not always match. In the SONIC trial, half of people in clinical remission still had endoscopic or blood marker evidence of residual active disease, while others with normal markers still had symptoms. Guidelines therefore suggest monitoring with biomarkers as well as symptoms, and your gastroenterologist chooses which tests suit you.
How is mild Crohn's disease monitored?
Usually with a combination of symptom review, blood tests such as CRP, hemoglobin and iron, stool fecal calprotectin, weight, and periodic imaging or ileocolonoscopy at intervals your gastroenterologist sets. The AGA suggests a biomarker and symptom approach over symptoms alone in people who feel well, and treats calprotectin under 150 with a normal CRP as ruling out active inflammation.
Does a normal fecal calprotectin mean my Crohn's is mild?
Not by itself. A normal calprotectin with a normal CRP makes active inflammation unlikely in someone who feels well, but calprotectin is less sensitive for small bowel disease, and in people with mild symptoms neither a normal nor a raised result is accurate enough on its own, according to the AGA. Results are read alongside symptoms and your doctor's plan.
Do people with mild Crohn's need treatment?
That is a decision for you and your gastroenterologist, and it depends on inflammation on testing, risk factors and symptoms. Experts describe a spectrum, from low-risk disease that is watched closely to higher-risk disease where earlier treatment is discussed. This article explains the monitoring evidence only. Please do not start, stop or change any medicine based on it.
What is the best way to track mild Crohn's disease over time?
Keep a dated log of stool frequency, night-time bowel movements, pain, blood, energy and weekly weight, next to each calprotectin, CRP and scope result. A paper diary works. A symptom tracker such as Clairop, which is free to download, keeps the same log and can produce a summary for appointments, so slow drift is visible rather than remembered.

Sources

  1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289-97. doi:10.1038/ajg.2009.579
  2. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430-8. doi:10.1016/j.cgh.2007.09.002
  3. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139(4):1147-55. doi:10.1053/j.gastro.2010.06.070
  4. Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68(3):423-33. doi:10.1136/gutjnl-2017-315568
  5. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130(3):650-6. doi:10.1053/j.gastro.2005.12.019
  6. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43(8):948-54. doi:10.1080/00365520801957149
  7. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-106. doi:10.1136/gutjnl-2019-318484
  8. Claytor J, Kumar P, Ananthakrishnan AN, Colombel JF, Agrawal M, Ungaro RC. Mild Crohn's disease: definition and management. Curr Gastroenterol Rep. 2023;25(3):45-51. doi:10.1007/s11894-023-00863-y
  9. Ha C. Management of patients with mild Crohn's disease. Gastroenterol Hepatol (N Y). 2024:345-7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11346010/
  10. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52(4):552-7. doi:10.1136/gut.52.4.552
  11. To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. Aliment Pharmacol Ther. 2016;43(5):549-61. doi:10.1111/apt.13511
  12. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 2001;120(5):1093-9. doi:10.1053/gast.2001.23231
  13. Freeman HJ. Natural history and long-term clinical course of Crohn's disease. World J Gastroenterol. 2014;20(1):31-6. doi:10.3748/wjg.v20.i1.31
  14. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014;63(1):88-95. doi:10.1136/gutjnl-2013-304984
  15. Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association between level of fecal calprotectin and progression of Crohn's disease. Clin Gastroenterol Hepatol. 2019;17(11):2269-76.e4. doi:10.1016/j.cgh.2019.02.017
  16. Ananthakrishnan AN, Adler J, Chachu KA, Nguyen NH, Siddique SM, Weiss JM, et al. AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease. Gastroenterology. 2023;165(6):1367-99. doi:10.1053/j.gastro.2023.09.029
  17. Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, et al. Deep remission at 1 year prevents progression of early Crohn's disease. Gastroenterology. 2020;159(1):139-47. doi:10.1053/j.gastro.2020.03.039
  18. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD). Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  19. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-55. doi:10.1016/S0140-6736(16)31711-1
  20. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-94. doi:10.1053/j.gastro.2011.01.055

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools